The multidisciplinary management of locally advanced rectal cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–254. doi: 10.3322/caac.21772
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Rectal cancer, version 5. 2023; [cited 2023 Nov 3]. Available from: http://www.nccn.org
   Google Scholar
• Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-prodige 2. J Clin Oncol. 2010;28(10):1638–1644. doi: 10.1200/JCO.2009.25.8376
   PubMed Web of Science ®Google Scholar
• De Felice F, Musio D, Magnante AL, et al. Disease control, survival, and toxicity outcome after intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a single-institution experience. Clin Colorectal Cancer. 2016;15(2):e17–22. doi: 10.1016/j.clcc.2016.02.006
   PubMed Web of Science ®Google Scholar
• Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–687. doi: 10.1016/S1470-2045(12)70187-0
   PubMed Web of Science ®Google Scholar
• O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04. J Clin Oncol. 2014;32(18):1927–1934. doi: 10.1200/JCO.2013.53.7753
   PubMed Web of Science ®Google Scholar
• Musio D, De Felice F, Bulzonetti N, et al. Neoadjuvant-intensified treatment for rectal cancer: time to change? World J Gastroenterol. 2013;19(20):3052–3061. doi: 10.3748/wjg.v19.i20.3052
   PubMed Web of Science ®Google Scholar
• Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR- 01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–2780. doi: 10.1200/JCO.2010.34.4911
   PubMed Web of Science ®Google Scholar
• Jiao D, Zhang R, Gong Z, et al. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study. Chin J Cancer Res. 2015;27(6):588–596. doi: 10.3978/j.issn.1000-9604.2015.12.05
   PubMed Web of Science ®Google Scholar
• De Felice F, Benevento I, Magnante AL, et al. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: oxaliplatin in neoadjuvant treatment for rectal cancer. BMC Cancer. 2017;17(1):325. doi: 10.1186/s12885-017-3323-4
   PubMedGoogle Scholar
• Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–1223. doi: 10.1002/bjs.5506
   PubMed Web of Science ®Google Scholar
• Cedermark B, Johansson H, Rutqvist LE. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm colorectal cancer study group. Cancer. 1995;75(9):2269–2275. doi: 10.1002/1097-0142(19950501)75:9<2269:AID-CNCR2820750913>3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–4625. doi: 10.1200/JCO.2006.06.7629
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740. doi: 10.1056/NEJMoa040694
   PubMed Web of Science ®Google Scholar
• Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–190. doi: 10.1016/S1470-2045(13)70599-0
   PubMed Web of Science ®Google Scholar
• Ciolina M, Caruso D, De Santis D, et al. Dynamic contrast-enhanced magnetic resonance imaging in locally advanced rectal cancer: role of perfusion parameters in the assessment of response to treatment. Radiol Med. 2019;124(5):331–338. doi: 10.1007/s11547-018-0978-0
   PubMed Web of Science ®Google Scholar
• Amodeo S, Rosman AS, Desiato V, et al. MRI-Based apparent diffusion coefficient for predicting pathologic response of rectal cancer after neoadjuvant therapy: systematic review and meta-analysis. AJR Am J Roentgenol. 2018;211(5):W205–16. doi: 10.2214/AJR.17.19135
   PubMed Web of Science ®Google Scholar
• De Felice F, Magnante AL, Musio D, et al. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Eur J Surg Oncol. 2017;43(7):1324–1329. doi: 10.1016/j.ejso.2017.03.010
   PubMed Web of Science ®Google Scholar
• Huang H, Han L, Guo J, et al. Multiphase and multiparameter MRI-based radiomics for prediction of tumor response to neoadjuvant therapy in locally advanced rectal cancer. Radiat Oncol. 2023;18(1):179. doi: 10.1186/s13014-023-02368-4
   PubMed Web of Science ®Google Scholar
• Musio D, De Felice F, Magnante AL, et al. Diffusion-weighted magnetic resonance application in response prediction before, during, and after neoadjuvant radiochemotherapy in primary rectal cancer carcinoma. Biomed Res Int. 2013;2013:1–5. doi: 10.1155/2013/740195
   Web of Science ®Google Scholar
• Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol. 2008;47(1):20–31. doi:10.1080/02841860701697720
   PubMed Web of Science ®Google Scholar
• Horvat N, Carlos Tavares Rocha C, Clemente Oliveira B, et al. MRI of rectal cancer: tumor staging, imaging techniques, and management. Radiographics. 2019;39(2):367–387. doi: 10.1148/rg.2019180114
   PubMed Web of Science ®Google Scholar
• Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ Preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–2556. doi: 10.1200/JCO.22.00032
   PubMed Web of Science ®Google Scholar
• Verheij FS, Omer DM, Williams H, et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2023;42(5):500–506. doi: 10.1200/JCO.23.01208
   PubMedGoogle Scholar
• Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–715. doi: 10.1016/S1470-2045(21)00079-6
   PubMed Web of Science ®Google Scholar
• Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42. doi: 10.1016/S1470-2045(20)30555-6
   PubMed Web of Science ®Google Scholar
• Ciseł B, Pietrzak L, Michalski W, et al. Long-course preoperative chemoradiation versus 5 × 5 gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298–1303. doi: 10.1093/annonc/mdz186
   PubMed Web of Science ®Google Scholar
• Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40(15):1681–1692. doi: 10.1200/JCO.21.01667
   PubMed Web of Science ®Google Scholar
• De Felice F, D’Ambrosio G, Iafrate F, et al. Intensified total neoadjuvant therapy in patients with locally advanced rectal cancer: a phase II trial. Clin Oncol (R Coll Radiol). 2021;33:788–794. doi: 10.1016/j.clon.2021.06.006
   PubMed Web of Science ®Google Scholar
• van der Valk MJM, Marijnen CAM, van Etten B, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - results of the international randomized RAPIDO-trial. Radiother Oncol. 2020;147:75–83. doi: 10.1016/j.radonc.2020.03.011
   PubMed Web of Science ®Google Scholar
• Dijkstra EA, Nilsson PJ, Hospers GAP, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023;278(4):e766–72. doi: 10.1097/SLA.0000000000005799
   PubMed Web of Science ®Google Scholar
• Ballal D, Raj P, Saklani AP. The RAPIDO trial—reduction in disease-related treatment failure does not translate into improved overall survival: a mystery solved! Colorectal Dis. 2023;25(8):1720–1721. doi: 10.1111/codi.16662
   PubMed Web of Science ®Google Scholar
• Schrag D, Shi Q, Weiser MR, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389(4):322–334. doi: 10.1056/NEJMoa2303269
   PubMed Web of Science ®Google Scholar
• Verheij FS, Omer DM, Williams H, et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2024;42(5):500–506. doi: 10.1200/JCO.23.01208
   PubMedGoogle Scholar
• Sauer R, Fietkau R, Wittekind C, et al. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis. 2003;5(5):406–415. doi: 10.1046/j.1463-1318.2003.00509.x
   PubMedGoogle Scholar
• Rectal cancer patients could Be spared the brutal effects of radiation. Article by Gina Kolata published on The New York Times; [ cited 2023 Jun 04]. Available from: https://www.nytimes.com/2023/06/04/health/rectal-cancer-radiation-treatment.html?smid=url-share
   Google Scholar
• Musella A, Vertechy L, Romito A, et al. Bevacizumab in ovarian cancer: state of the art and unanswered questions. Chemotherapy. 2017;62(2):111–120. doi: 10.1159/000448942
   PubMed Web of Science ®Google Scholar
• Marchetti C, De Felice F, Romito A, et al. Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments. Semin Cancer Biol. 2021;77:144–166. doi: 10.1016/j.semcancer.2021.08.011
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Tsoutsou P, et al. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a phase II study. Int J Radiat Oncol Biol Phys. 2011;80(2):492–498. doi: 10.1016/j.ijrobp.2010.02.037
   PubMed Web of Science ®Google Scholar
• Salazar R, Capdevila J, Laquente B, et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015;15(1):60. doi: 10.1186/s12885-015-1053-z
   PubMedGoogle Scholar
• Lancet Oncology T. Cancer immunotherapy: enthusiasm and reality aligning at last. Lancet Oncol. 2015;16(5):475. doi: 10.1016/S1470-2045(15)70211-1
   PubMed Web of Science ®Google Scholar
• De Felice F, Marchetti C, Palaia I, et al. Immune check-point in cervical cancer. Crit Rev Oncol Hematol. 2018;129:40–43. doi: 10.1016/j.critrevonc.2018.06.006
   PubMed Web of Science ®Google Scholar
• Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363–2376. doi: 10.1056/NEJMoa2201445
   PubMed Web of Science ®Google Scholar
• Chen G, Jin Y, Guan WL, et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023;8(5):422–431. doi: 10.1016/S2468-1253(22)00439-3
   PubMed Web of Science ®Google Scholar
• Fokas E, Appelt A, Glynne-Jones R, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo) radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18(12):805–816. doi: 10.1038/s41571-021-00538-5
   PubMed Web of Science ®Google Scholar
• Fokas E, Glynne-Jones R, Appelt A, et al. Outcome measures in multimodal rectal cancer trials. Lancet Oncol. 2020;21(5):e252–64. doi: 10.1016/S1470-2045(20)30024-3
   PubMed Web of Science ®Google Scholar
• De Felice F, Crocetti D, Maiuri V, et al. Locally advanced rectal cancer: treatment approach in elderly patients. Curr Treat Options Oncol. 2020;21(1):1. doi: 10.1007/s11864-019-0692-8
   PubMed Web of Science ®Google Scholar